ASX Announcement Recce Pharmaceuticals Opening R&D Address at World Anti-Microbial Resistance Congress 2021 Sydney Australia, 8 November 2021: Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (Company), the Company developing New Classes of Synthetic Anti-infectives, today announced it will be delivering the Opening R&D Address at the World Anti-Microbial Resistance (AMR) Congress 8th-9th November 2021. Recce Chairman, Dr John Prendergast will deliver the 20-minute Opening R&D Address, highlighting the urgent need for new antibiotics to address the rapidly growing threat of AMR. Dr Prendergast’s presentation “Synthetic Anti-Infectives: Embracing New Technology”, highlighting Recce’s unique Mechanisms of Action, infectious disease pipeline of new drug candidates – positioning Recce as a sign of new hope in the global fight against superbugs on the international stage. The two-day World AMR Congress held in Washington DC is the largest AMR conference in the world with more than 1,000 attendees from over 50 countries. The congress attracts industry leaders, clinicians, healthcare payers, and medical regulators from around the world.
RCE Price at posting:
94.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)